NCT06173531Phase 3Completed

Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Study sponsor: ACADIA Pharmaceuticals Inc. · ACAD

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-08-19Actual
Enrollment · participants175Actual
Source updated2026-10-15Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 6 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change from Baseline at Week 12 in caregiver-rated Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score Description: The HQ-CT is a nine-item questionnaire designed to be completed by caregivers of subjects with PWS. It is a revision of the 11-item HPWSQ-R and has been further validated. The Foundation for Prader-Willi Research has made the HQ-CT available for clinical studies in PWS, and it is the consensus instrument within the PWS research community for measuring observable behaviors that stem from subjects' excessive drive to eat. The HQ-CT should be completed by the same caregiver throughout the study. The HQ-CT will be administered to the caregiver by a rater using standardized prompts. The Food Safe Zone should be administered immediately before administration of the HQ-CT. A higher score on the HQ-CT indicates greater severity of hyperphagia. Time frame: Baseline to Week 12. After: Measure: Change From Baseline at Week 12 in Hyperphagia Questionnaire for Clinical Trials (HQ-CT) Score Description: The HQ-CT is a caregiver-reported, 9-item assessment of observable hyperphagia-related behaviors in participants with PWS. The questionnaire is administered to the caregiver by a trained rater using standardized prompts, and the same caregiver is expected to complete the assessment throughout the study whenever possible. Each item is scored from 0 to 4, resulting in a total score ranging from 0 to 36, with higher scores indicating greater severity of hyperphagia. A decrease from baseline reflects improvement, and a reduction of 7.7 points has been identified as a clinically meaningful within-participant improvement. Time frame: Baseline to Week 12.

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 170 participants (planned). After: 175 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Oct 2025. After: 19 Aug 2025.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview